logo-loader

Shield Therapeutics' on cusp of US market expansion with focus on commercialising Accrufer

Published: 14:28 25 Aug 2021 BST

Shield Therapeutics PLC (LSE:STX, FRA:1JS)'s (LON:STX, OTCQX:SHIEF) investment case is presented by Proactive Research Analyst John Savin who explains how the firm hinges on the success of their US launch of commercialising Accrufer.

This treatment is for iron deficiency or anaemia and as Savin explains Shield owns the product, which means they would be taking all the profit but, most importantly, controlling the process.

He says the market is large with 10mln oral prescriptions a year. And Accrufer offers excellent tolerability and efficacy compared to other oral iron products.

Click here to read Proactive analysts' Robin Davison & John Savin's latest research update on 'Shield Therapeutics: Master of its own destiny'

Shield Therapeutics' pricing will be "key metric" - Proactive Research Analyst

Proactive Research Analyst Robin Davison speaks to Thomas Warner after publishing a new research note on iron defiency-focused commercial-stage specialty pharmaceutical company Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) Davison gives an overview of what readers can expect from the note,...

on 3/10/23